IBT
IMVT icon

International Biotechnology Trust’s Immunovant IMVT Stock Holding History

International Biotechnology Trust’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-233
Closed -$60K – 75
2022
Q2 		$60K Sell
233
-59,767
-100% -$258K 0.63% 36
2022
Q1 		$851K Hold
60,000
– – 0.19% 58
2021
Q4 		$511K Hold
60,000
– – 0.11% 67
2021
Q3 		$521K Hold
60,000
– – 0.13% 59
2021
Q2 		$634K Buy
+60,000
New +$838K 0.17% 57

Other funds holding IMVT

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

International Biotechnology Trust's IMVT Position: Q3 2022 in Review

International Biotechnology Trust sold out of Immunovant (IMVT) in Q3 2022, closing a stake of 233 shares — an estimated $60K sold.

International Biotechnology Trust first reported a position in IMVT in Q2 2021 and held it in 5 quarters. The position peaked at $851K in Q1 2022. 112 funds tracked by Wall St. Rank hold IMVT as of Q3 2022.

  • International Biotechnology Trust reported no remaining Immunovant position as of Q3 2022 after selling out during the quarter.
  • International Biotechnology Trust sold 233 Immunovant shares in Q3 2022, an estimated $60K.
  • International Biotechnology Trust first reported a position in Immunovant in Q2 2021 and held it in 5 quarters.
  • International Biotechnology Trust's Immunovant position peaked at $851K in Q1 2022.
  • 112 funds tracked by Wall St. Rank held Immunovant as of Q3 2022.

Based on International Biotechnology Trust's 13F filing for Q3 2022, filed 8 Nov 2022.